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Antibacterial and antifungal peptides have increasingly been used to combat the antibiotic-resistant microbes in recent years. KW-
13, a novel cationic 𝛼-helical antibacterial peptide consisting of 13 amino acid residues, was designed and chemically synthesized.
The peptide has a net charge of +6with a total hydrophobic ratio of 38%.The antibacterial experiments revealed that KW-13 strongly
inhibited the growth of human pathogenic bacteria with minimal inhibitory concentrations of 4 and 16𝜇g/mL for Staphylococcus
epidermidis and Staphylococcus aureus, respectively, while the hemolytic assay showed that this peptide did not destroy human red
blood cells in vitro. Scanning electron microscopy imaging of Escherichia coli confirmed that KW-13 can damage the membrane of
bacterial cells. Thus, this peptide could be a potential candidate for the treatment of infectious diseases.
1. Introduction
Drug resistance to microorganisms, including bacteria such
as staphylococci, enterococci and Escherichia coli, fungi,
viruses and parasites, has become a major challenge for
humanhealthworldwide. Antimicrobial peptides (AMPs) are
good candidates as new antibiotics since they are natural
defenses ofmost living organisms against invading pathogens
[1–3]. Some of them have also been found showing antitumor
and spermicidal activities [4, 5]. These AMPs are relatively
small (<10 kDa in MW), cationic, and amphipathic peptides
with variable length, sequence, and structure. The first AMP
cecropin was discovered from Hyalophora cecropia in 1981
[6]. In the following years, peptides with antibacterial activity
have been found in thewhole natural kingdom, frombacteria,
insects, and amphibians to mammals [7–9]. To exert antimi-
crobial action, they use a common “carpet” mechanism,
in which they accumulate on the bacterial membrane up
to a threshold concentration, and then cause membrane
permeabilization/disintegration [10].
The AMPs are classified into five groups [11]: (1) peptides
that form 𝛼-helical structure, (2) peptides that are rich in
cysteine residues, (3) peptides that form 𝛽-sheet structure,
(4) peptides that are rich in regular amino acids, namely,
histidine, arginine, and proline, and (5) peptides that are
composed of rare and modified amino acids. These general
features can be used as guidance for design and synthesis of
potent AMPs.
The natural AMPs are far from perfect and some of them
cause toxicity to the eukaryotes. For example, the strong
antibacterial activity is often accompanied with hemolysis
to the eukaryotes. So the main purpose of this study is to
improve their antibacterial activity and reduce toxicity to
eukaryotes. Rational design and thereafter chemical synthesis
are important approaches in the search for substitutes of
conventional antibiotics because it can overcome the limi-
tations in large-scale production and application of natural
peptides, such as the low specific activity and the small
amounts recovered from natural sources. There are many
databases and software for active peptide design.The website
at http://web.expasy.org/blast/ is a useful tool for sequence
analysis and secondary structure prediction. Accelrys Insight
II provides powerful function for studying structure and
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Table 1: The sequences of six designed peptides.
Name Sequence Design
KWKK-13 KWKKPKLLKKLLK N-terminal domain contains three cationic lysine residues and C-terminalis a standard 𝛼-helix (KLLK). They are connected with proline.
KW-13 KWKYPKLLKKLLK N-terminal domain contains two cationic lysine residues and C-terminal isa standard 𝛼-helix (KLLK). They are connected with proline.
RFFR-15 RRWWRFPRFFRRFFR-NH2
N-terminal domain contains three cationic arginines and C-terminal is a
standard 𝛼-helix (RFFR). They are connected with proline. C-terminal
amidation stabilizes the peptide.
RFPP-18 RRWWRFPPPRFPPRFPPP-NH2
N-terminal domain contains three cationic arginines and C-terminal is a
standard 𝛼-helix (RFPP). They are connected with proline. C-terminal
amidation stabilizes the peptide. This sequence contains more proline.
KPV-13 KWKLFKKIWGKPV-NH2 Hybrid peptide based on the AMPs in the database. The N-terminal is fromcecropin A1 and C-terminal is fromMSH.
KPV-8 KFRWGKPV-NH2 Hybrid peptide based on the AMPs in the database. The N-terminal is fromcecropin A1 and C-terminal is fromMSH.
target-based drug design. Antimicrobial Peptide Database
(APD) is a specialized database containing many antimicro-
bial peptides and it provides query, prediction, and design
of peptides [12, 13]. It has been established that the physico-
chemical properties of AMPs, including secondary structure,
overall charge and hydrophobicity, affect their interaction
with model membranes and mammalian cells [14–17]. Most
of AMPs fold into an amphipathic 𝛼-helical conformation
when interacting with the target microorganism. With the
development of these structure-activity relationship and
mechanism research, it is feasible to design AMPs, which
are more efficient to kill microorganisms and less toxic to
eukaryotes.
In this study, we designed and synthesized six peptides
based on characteristics of natural AMPs that are preferably
cationic, with 𝛼-helix, and with more than 30% of hydropho-
bic residues. One of them KW-13 showed potent inhibitory
activity against bacteria without hemolytic action on human
blood red cells. This peptide could be a potential candidate
for the treatment of infectious diseases.
2. Materials and Methods
2.1. Design of Peptide. The antibacterial peptides were
designed using the APD (http://aps.unmc.edu/AP/main
.php) [12, 13]. The peptide sequences were chosen based on
the following rules: (1) containing positive charged amino
acids, (2) containing 𝛼-helix, and (3) containing hydrophobic
amino acids. Variation of the physicochemical features pre-
dicted according to this database is shown in Table 1.
2.2. The Strains and Growth Conditions. Two Gram-positive
bacteria, 3 Gram-negative bacteria, and 2 fungi were selected
to measure antibacterial activity of peptides. The strains
were provided by Department of Microbiology in China
Pharmaceutical University and were stored at 4∘C until use.
The species and culture condition of these bacterial strains are
summarized in Table 3.
2.3. Peptide Synthesis and Purification. Peptides were synthe-
sized by the Fmoc (N-[9-fluorenyl]-methoxycarbonyl) chem-
istry according to the literature procedure [18, 19]. Protected
amino acids were coupled by in situ activation with N,N-
diisopropylethylamine (DIEA) and N-hydroxybenzotriazole
(HOBt). Deprotection was performedwith 20% piperidine in
N,N-dimethylformamide (DMF). The protected side chains
of amino acid residues and the cleavage of the peptide
from the solid support were performed by 95% trifluo-
roacetic acid (TFA)/2.5% triisopropylsilane (TIS)/2.5% water
for 1 h at room temperature. After cleavage from resin, the
peptides were purified by preparative reverse-phase HPLC
(BioLogic Duoflow system) on a Kromasil C18 column (250×
10mm, particle size 5𝜇m, pore size 100 Å). The elution was
achieved with a linear gradient of 0.05% TFA in 5%methanol
(A) and 0.05% TFA in 95% methanol (B) at a flow rate
of 5mL/min (57–64%B in 30min). The main peak was
pooled, lyophilized, and stored at −20∘C. The purity of the
peptide was evaluated using analytical reverse-phase HPLC
(Shimadzu LC-10AT) on a Lichrospher C18 column (250 ×
4.6mm) in the same mobile phase with a linear gradient at
a flow rate of 1mL/min (49–54%B in 20min). The synthetic
peptides were confirmed by electrospray mass spectrometry.
2.4. Measurement of Antibacterial Activity. Antimicrobial
activity was evaluated using an inhibition zone assay or deter-
mination of the minimal inhibitory concentration (MIC)
value with minor modifications as described previously [20]:
(1) Inhibition zone assay: agar plates were seeded with
strains (about 106 cells in 10mL of 1% agar medium).
Wells (3mm in diameter) were punched out and a
5 𝜇L peptide sample dissolved in water was loaded.
Controls were loaded with water. After incubation at
37∘C overnight, the diameter of the inhibition zone
was determined.
(2) Determination of the MIC value: MICs were deter-
mined using a standard serial dilution method in


























































































































Figure 1: ClustalW alignment of the KW-13 with the most similar
AMPs in the APD database.
appropriate medium for each bacterial strain listed in
Table 3. In brief, 1mL of different peptides dilution
solutions was poured into a series of sterile plates, and
then 9mL appropriatemedium that was preincubated
at 37∘Cwas added into a plate andwasmixed gently to
reach various concentrations (512, 256, 128, 64, 32, 16,
8, 4, 2, 1, and 0.5 𝜇g/mL). Bacteria were added to the
96-well plates. The amount of bacteria for each spot
is approximately 104 to 105 CFU/mL. After incubating
the inoculated plate at 37∘C for 16 to 18 hours, MICs
were determined as the lowest peptide concentration
that inhibited bacterial growth. All MICs were deter-
mined in two independent experiments performed in
duplicate.
2.5. Measurement of Hemolytic Activity (MHC). Hemolytic
activity was determined by the procedure of Yoshida et al.
with slight modifications [21]. Fresh human blood (1mL) was
centrifuged at 1000×g for 5min and the precipitates were
collected and then washed 3 times with phosphate buffered
saline (PBS) (pH 7.4). Precipitates were resuspended in 4-
fold volumes of PBS.Then, 995 𝜇L of PBS solution containing
serial diluted peptides was added to a human erythrocyte
solution of 5𝜇L. The resulting solution was incubated at
37∘C for 1 h and was centrifuged at 1000×g for 5min. The
supernatant was diluted 5-fold with PBS and was monitored
at 415 nm using a UV spectrophotometer. Zero hemolysis
(blank) and 100% hemolysis were determined in PBS and 1%
Triton X-100, respectively.
2.6. Scanning Electron Microscopy. A mid-logarithmic phase
culture of Escherichia coliwas exposed to KW-13 (256𝜇g/mL)
or water at 37∘C for 2 h. Bacteria were precipitated by
centrifugation at 5000 rpm for 5min and washed 3 times
in PBS (pH 7.4). The supernatants were removed and the
pellets were fixed in 800 𝜇L of 2.5% glutaraldehyde in 0.1M
PBS at 4∘C for 24 h. The fixed bacteria were centrifuged at
5000 rpm for 10min, washed 2 times with 0.1M PBS, and
then step-dehydrated with 70%, 80%, 90%, and 100% ethanol.
After drying and gold coating, the samples were examined by
scanning electron microscopy.
2.7. HomologywithOther Antimicrobial Peptides. AClustalW
tool was used for peptide sequences alignment [22]. The
results are presented in Table 4 and Figure 1.
Table 2: Physicochemical properties of KW-13 peptide.
Primary structure KWKYPKLLKKLLK
Hydrophobic amino acid I: 0, V: 0, L: 0, F: 0, C: 0, A: 0,W: 1
MW (Da) 1686.02
Cationicity 6
Total hydrophobic ratio 38%
Protein-binding potential
(kcal/mol) 0.87






Staphylococcus aureus 37 Luria-Bertani
Staphylococcus epidermidis 37 Luria-Bertani
Escherichia coli 37 Luria-Bertani
Klebsiella pneumoniae 37 Luria-Bertani
Pseudomonas aeruginosa 37 Luria-Bertani
Monilia albicans 30 Martin Broth, Modified
Aspergillus niger 30 Martin Broth, Modified
Luria-Bertani (LB): peptone 10 g/L, yeast extract 5 g/L, and NaCl 10 g/L, pH
7.4 after sterilization; Martin Broth, Modified: peptone 10 g/L, yeast extract
2 g/L, glucose 20 g/L, dipotassium hydrogen phosphate 1 g/L, and MgSO
4
0.5 g/L, pH 6.4 ± 0.2 after sterilization.
2.8. Secondary Structure Prediction. Secondary structure
modeling was performed from a template model con-
structed by putative conserved domains associated with
the primary sequence of the novel peptide. This was
conducted at theNCBI server using BLAST (http://www.ncbi
.nlm.nih.gov/blast/Blast.cgi). The three-dimensional struc-
ture of peptide was analyzed using the Accelrys discovery
studio.
3. Results and Discussion
3.1. Peptide Design and Structure Prediction. Six peptides
were designed based on characteristics of natural AMPs,
including small size, cationicity, amphipathicity, and 𝛼-helix.
Sequences of peptides and their design explanation are listed
in Table 1. KW-13 consists of 13 amino acid residues, its N-
terminal domain contains two cationic lysine residues, C-
terminal contains a standard 𝛼-helix (KLLK), and these two
domains are connected with a proline residue. The APD-
based prediction indicated that KW-13 has 4 Leu and 1 Trp,
showing a APD defined total hydrophobic ratio of 38%,
and 6 Lys, showing +6 positive net charge, and that KW-
13 may form alpha helices and at least 3 residues on the
same hydrophobic surface. This peptide may interact with
membranes and therefore becomes an antimicrobial peptide.
The physicochemical properties of KW-13 are summarized
in Table 2. The alignment was performed by ClustalW
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Table 4: Peptides with homology to KW-13.
Peptidea Source Homology
KW-13 Synthetic, de novo design
AP00143 Synthetic, de novo design 61.53%
AP00506 Synthesis 50%
AP00501 Synthesis 50%
AP00142 Synthetic, database-aided design usingfreq. occurring residues 50%
AP00859 Rana temporaria 46.15%
aThe homologue peptides are identified according to APD ID.
Figure 2: The secondary structure model for KW-13. The color
codes are red for the regular 𝛼-helix and white for random coil.
tool to compare the degree of homology of KW-13 with
other antimicrobial peptides. The results showed that KW-
13 shared similarity percentages of 61.53%, 50%, 50%, 50%,
and 46.15% with known antibacterial peptides, AP00143,
AP00506, AP00501, AP00142, and AP00859, respectively
(Table 4 andFigure 1).The three-dimensional structure of this
peptide was constructed by homology modeling using the
tool ofAccelrys discovery studio (Figure 2), showing that ran-
dom coil and 𝛼-helix distributes in two well-defined zones,
N-terminus and C-terminus, respectively. Analysis using
the ExPASyMW/pI tool (http://web.expasy.org/compute pi/)
indicated that the PI of KW-13 is 10.40 [23]. BLAST searches
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) showed that
KW-13 is a novel peptide.
3.2. Peptide Synthesis andCharacterization. Six peptideswere
chemically synthesized by a solid-phase peptide synthesis
method and then were purified by preparative RP-HPLC on
C18 column.Thepurity of KW-13was above 99%according to
analytical HPLC. Its molecular weight was determined by
mass spectrometer analysis and the result was consistent with
the calculated molecular weight of 1686.20Da.
3.3. Antimicrobial Activity. Antimicrobial activities of six
peptides (KW-13, RFFR-15, RFPP-18, KWKK-13, KPV-13, and
KPV-8) were investigated against several microorganisms.
The MICs were determined and summarized in Table 5.
RFFR-15, RFPP-18, KWKK-13, KPV-13, and KPV-8 showed
weak activities against bacteria and did not show activity
against fungi. Interestingly, KW-13 showed potent activity
against bacteria. The MICs of KW-13 for Staphylococcus
aureus, Staphylococcus epidermidis, Escherichia coli,Klebsiella
pneumoniae, and Pseudomonas aeruginosa were comparable
to ampicillin and streptomycin sulfate which have been
used in clinic. The results also showed that KW-13 strongly
inhibited the growth of Gram-positive bacteria (G+) such as
Staphylococcus aureus (16 𝜇g/mL) and Staphylococcus epider-
midis (4 𝜇g/mL), indicating that KW-13 was more powerful
thanMagainin 1, an antimicrobial peptide fromXenopus skin
inhibiting Staphylococcus aureus, E. coli, Klebsiella pneumo-
niae, and Pseudomonas aeruginosa [24]. However, KW-13 was
less effective against fungi, such as Aspergillus niger (256
𝜇g/mL).
3.4. Scanning Electron Microscopy. Scanning electron
microscopy was used to examine whether KW-13 can damage
E. coli cell membranes. E. coli treated with KW-13
(256𝜇g/mL) were largely destroyed and numerous cellular
fragments were observed (Figures 3(b) and 3(c)), whereas the
control bacteria showednormal intact surface (Figure 3(a)). It
was reported that cationicAMPswith net positive charges can
interact with negatively charged groups in G−bacteria
membranes such as lipopolysaccharides, leading to the
formation of “wormholes” and the collapse of the bacteria
[25]. Membrane disruption can lead to leakage of ions and
metabolites, depolarization, and ultimately cell death. This
result indicated that KW-13 could kill E. coli by destroying
the cell membrane.
3.5. Hemolytic Assay. KW-13 was challenged with hemolytic
assay against human blood red cell (RBC) at 10 𝜇g/mL, 40
𝜇g/mL, 160 𝜇g/mL, and 640 𝜇g/mL. No significant hemolysis
(<1%) was observed even at high concentration (640 𝜇g/mL),
while a well-known hemolytic peptide, Melittin, caused the
lysis of whole erythrocytes at a concentration below
40 𝜇g/mL. Our results indicated KW-13 was not toxic to
human RBCs.
4. Conclusions
In conclusion, KW-13, a novel cationic 𝛼-helical antibacterial
peptide, showed potent inhibitory activity against human
pathogenic bacteria without destroying human red blood
cells. This peptide inhibited bacterial growth by destroying
the membrane of it. Further works should be performed in
animal models to confirm the antibacterial function of KW-
13 in vivo.
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Table 5: Antimicrobial activities (MIC) of peptide against bacteria and fungi.
Strain MIC (𝜇g/mL)
KW-13 RFFR-15 RFPP-18 KWKK-13 KPV-13 KPV-8
Staphylococcus aureus 16 64 >512 >512 >512 >512
Staphylococcus epidermidis 4 128 512 >512 32 >512
Escherichia coli 64 256 128 256 512 >512
Klebsiella aeruginosa 128 >512 >512 >512 >512 >512
Pseudomonas aeruginosa 128 >512 256 >512 >512 >512
Monilia albicans ND ND ND ND ND ND
Aspergillus niger 256 >512 >512 >512 >512 >512
MIC: minimal inhibitory concentration. These concentrations represent mean values of three independent experiments performed in duplicate. ND denotes







Figure 3: Scanning electron micrographs of E. coli treated with KW-13. E. coli in mid-logarithmic growth was incubated with antibacterial
peptide KW-13 for 2.5 h. (a) Untreated E. coli showing a normal intact cell surface. Scale bar is 3𝜇m. (b) Treated with 256 𝜇g/mL KW-13 for
2.5 h, the E. coli cell membranes were disrupted. Scale bar is 3𝜇m. (c) The amplification of (b) in different visual field. Scale bar is 1 𝜇m.
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